|
1
|
Pasetto A and Lu YC: Single-cell TCR and
transcriptome analysis: An indispensable tool for studying T-cell
biology and cancer immunotherapy. Front Immunol. 12:6890912021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Papadakis M, Karniadakis I, Mazonakis N,
Akinosoglou K, Tsioutis C and Spernovasilis N: Immune checkpoint
inhibitors and infection: What is the interplay? In Vivo.
37:2409–2420. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong X, Zhang J, Chen S, Wang X, Xi Q,
Shen H and Zhang R: Immune checkpoint inhibitors: Breakthroughs in
cancer treatment. Cancer Biol Med. j.issn.2095-3941.2024.0055.
2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, et al: Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Zhong Y, Zhang Z, Zhou K, Huang Z,
Yu H, Liu L, Liu S, Yang H, Zhou J, et al: Characteristics and
clinical significance of T-cell receptor repertoire in
hepatocellular carcinoma. Front Immunol. 13:8472632022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robert L, Tsoi J, Wang X, Emerson R, Homet
B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, et al:
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Clin Cancer Res. 20:2424–2432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Charles J, Mouret S, Challende I, Leccia
MT, De Fraipont F, Perez S, Plantier N, Plumas J, Manuel M,
Chaperot L and Aspord C: T-cell receptor diversity as a prognostic
biomarker in melanoma patients. Pigment Cell Melanoma Res.
33:612–624. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaplin DD: Overview of the immune
response. J Allergy Clin Immunol. 125 (2 Suppl 2):S3–S23. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonilla FA and Oettgen HC: Adaptive
immunity. J Allergy Clin Immunol. 125 (2 Suppl 2):S33–S40. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gielis S, Moris P, Bittremieux W, De
Neuter N, Ogunjimi B, Laukens K and Meysman P: Detection of
enriched T cell epitope specificity in full T cell receptor
sequence repertoires. Front Immunol. 10:28202019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lo Presti E, Dieli F and Meraviglia S:
Tumor-infiltrating γδ T lymphocytes: pathogenic role, clinical
significance, and differential programing in the tumor
microenvironment. Front Immunol. 5:6072014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roth DB: V(D)J recombination: Mechanism,
errors, and fidelity. Microbiol Spectr.
2:10.1128/microbiolspec.MDNA3. 0041–2014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schatz DG and Ji Y: Recombination centres
and the orchestration of V(D)J recombination. Nat Rev Immunol.
11:251–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahe E, Pugh T and Kamel-Reid S: T cell
clonality assessment: Past, present and future. J Clin Pathol.
71:195–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosati E, Dowds CM, Liaskou E, Henriksen
EKK, Karlsen TH and Franke A: Overview of methodologies for T-cell
receptor repertoire analysis. BMC Biotechnol. 17:612017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rossjohn J, Gras S, Miles JJ, Turner SJ,
Godfrey DI and McCluskey J: T cell antigen receptor recognition of
antigen-presenting molecules. Annu Rev Immunol. 33:169–200. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laydon DJ, Bangham CRM and Asquith B:
Estimating T-cell repertoire diversity: Limitations of classical
estimators and a new approach. Philos Trans R Soc Lond B Biol Sci.
370:201402912015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Woodsworth DJ, Castellarin M and Holt RA:
Sequence analysis of T-cell repertoires in health and disease.
Genome Med. 5:982013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pai JA and Satpathy AT: High-throughput
and single-cell T cell receptor sequencing technologies. Nat
Methods. 18:881–892. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shugay M, Britanova OV, Merzlyak EM,
Turchaninova MA, Mamedov IZ, Tuganbaev TR, Bolotin DA, Staroverov
DB, Putintseva EV, Plevova K, et al: Towards error-free profiling
of immune repertoires. Nat Methods. 11:653–655. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Zhang W, Zeng X, Zhang R, Du Y,
Hong X, Cao H, Su Z, Wang C, Wu J, et al: Systematic comparative
evaluation of methods for investigating the TCRβ repertoire. PLoS
One. 11:e01524642016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carlson CS, Emerson RO, Sherwood AM,
Desmarais C, Chung MW, Parsons JM, Steen MS,
LaMadrid-Herrmannsfeldt MA, Williamson DW, Livingston RJ, et al:
Using synthetic templates to design an unbiased multiplex PCR
assay. Nat Commun. 4:26802013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
No authors listed. Rapid amplification of
5′ complementary DNA ends (5′ RACE). Nat Methods. 2:629–630. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu YY, Machleder EM, Chenchik A, Li R and
Siebert PD: Reverse transcriptase template switching: A SMART
approach for full-length cDNA library construction. Biotechniques.
30:892–897. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart JJ, Lee CY, Ibrahim S, Watts P,
Shlomchik M, Weigert M and Litwin S: A Shannon entropy analysis of
immunoglobulin and T cell receptor. Mol Immunol. 34:1067–1082.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shannon CE: A mathematical theory of
communication. Bell Syst Tech J. 27:379–423. 1948. View Article : Google Scholar
|
|
27
|
Pielou EC: The measurement of diversity in
different types of biological collections. J Theor Biol.
13:131–144. 1966. View Article : Google Scholar
|
|
28
|
Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP,
Su XK, Jiang J, Pan YM, Mao SL, Mao XF and Luo W: TCR repertoire as
a novel indicator for immune monitoring and prognosis assessment of
patients with cervical cancer. Front Immunol. 9:27292018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan Y, Gao J, Lin J, Ma Y, Hou Z, Lin Y,
Wen S, Pan M, Lu F and Huang H: High-dimensional single-cell
analysis unveils distinct immune signatures of peripheral blood in
patients with pancreatic ductal adenocarcinoma. Front Endocrinol
(Lausanne). 14:11815382023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Zhang B, Yang Y, Zhu J, Cheng S,
Mao Y, Feng L and Xiao T: Characterization of distinct T cell
receptor repertoires in tumor and distant non-tumor tissues from
lung cancer patients. Genomics Proteomics Bioinformatics.
17:287–296. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song Z, Chen X, Shi Y, Huang R, Wang W,
Zhu K, Lin S, Wang M, Tian G, Yang J and Chen G: Evaluating the
potential of t cell receptor repertoires in predicting the
prognosis of resectable non-small cell lung cancers. Mol Ther
Methods Clin Dev. 18:73–83. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Xu Y, Zhao M, Liu Y, Gong M, Xie
C, Wu H and Wang Z: High-throughput T cell receptor sequencing
reveals distinct repertoires between tumor and adjacent non-tumor
tissues in HBV-associated HCC. Oncoimmunology. 5:e12190102016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin KR, Deng FW, Jin YB, Chen XP, Pan YM,
Cui JH, You ZX, Chen HW and Luo W: T cell receptor repertoire
profiling predicts the prognosis of HBV-associated hepatocellular
carcinoma. Cancer Med. 7:3755–3762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sherwood AM, Emerson RO, Scherer D,
Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D,
Schirmacher P, et al: Tumor-infiltrating lymphocytes in colorectal
tumors display a diversity of T cell receptor sequences that differ
from the T cells in adjacent mucosal tissue. Cancer Immunol
Immunother. 62:1453–1461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma J, Sun G, Zhu P, Liu S, Ou M, Chen Z,
Zou C, Chan FL, Dai Y and Sui W: Determination of the complexity
and diversity of the TCR β-chain CDR3 repertoire in bladder cancer
using high-throughput sequencing. Oncol Lett. 17:3808–3816.
2019.PubMed/NCBI
|
|
36
|
Zhang J, Wang Y, Huang Y, Tan X, Xu J, Yan
Q, Tan J, Zhang Y, Zhang J, Ma Q, et al: Characterization of T cell
receptor repertoire in penile cancer. Cancer Immunol Immunother.
73:242024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang T, Wang C, Wu J, He C, Zhang W, Liu
J, Zhang R, Lv Y, Li Y, Zeng X, et al: The different T-cell
receptor repertoires in breast cancer tumors, draining lymph nodes,
and adjacent tissues. Cancer Immunol Res. 5:148–156. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Z, Zhang C, Pan Y, Xu R, Xu C, Chen
Z, Lu Z and Ke Y: T cell receptor β-chain repertoire analysis
reveals intratumour heterogeneity of tumour-infiltrating
lymphocytes in oesophageal squamous cell carcinoma. J Pathol.
239:450–458. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cha E, Klinger M, Hou Y, Cummings C, Ribas
A, Faham M and Fong L: Improved survival with T cell clonotype
stability after anti-CTLA-4 treatment in cancer patients. Sci
Transl Med. 6:238ra702014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu Y, Zhao F, Li Z and Yu J: Current
landscape and future directions of biomarkers for predicting
responses to immune checkpoint inhibitors. Cancer Manag Res.
10:2475–2488. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z,
Liu R, Zhang Y, Li Y, Yin G, et al: Peripheral blood T-cell
receptor repertoire as a predictor of clinical outcomes in
gastrointestinal cancer patients treated with PD-1 inhibitor. Clin
Transl Oncol. 23:1646–1656. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Roh W, Chen PL, Reuben A, Spencer CN,
Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy
SM, et al: Integrated molecular analysis of tumor biopsies on
sequential CTLA-4 and PD-1 blockade reveals markers of response and
resistance. Sci Transl Med. 9:eaah35602017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kato T, Kiyotani K, Tomiyama E, Koh Y,
Matsushita M, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Hatano K, et
al: Peripheral T cell receptor repertoire features predict durable
responses to anti-PD-1 inhibitor monotherapy in advanced renal cell
carcinoma. Oncoimmunology. 10:18629482021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu YY, Yang QF, Yang JS, Cao RB, Liang
JY, Liu YT, Zeng YL, Chen S, Xia XF, Zhang K and Liu L:
Characteristics and prognostic significance of profiling the
peripheral blood T-cell receptor repertoire in patients with
advanced lung cancer. Int J Cancer. 145:1423–1431. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen YT, Hsu HC, Lee YS, Liu H, Tan BC,
Chin CY, Chang IY and Yang CY: Longitudinal high-throughput
sequencing of the T-cell receptor repertoire reveals dynamic change
and prognostic significance of peripheral blood TCR diversity in
metastatic colorectal cancer during chemotherapy. Front Immunol.
12:7434482022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sheikh N, Cham J, Zhang L, DeVries T,
Letarte S, Pufnock J, Hamm D, Trager J and Fong L: Clonotypic
diversification of intratumoral T cells following sipuleucel-T
treatment in prostate cancer subjects. Cancer Res. 76:3711–3718.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Frankowska K, Zarobkiewicz M, Dąbrowska I
and Bojarska-Junak A: Tumor infiltrating lymphocytes and
radiological picture of the tumor. Med Oncol. 40:1762023.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kazemi MH, Sadri M, Najafi A, Rahimi A,
Baghernejadan Z, Khorramdelazad H and Falak R: Tumor-infiltrating
lymphocytes for treatment of solid tumors: It takes two to tango?
Front Immunol. 13:10189622022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Whiteside TL: Tumor-infiltrating
lymphocytes and their role in solid tumor progression. Exp Suppl.
113:89–106. 2022.PubMed/NCBI
|
|
53
|
Giraldo NA, Becht E, Remark R, Damotte D,
Sautès-Fridman C and Fridman WH: The immune contexture of primary
and metastatic human tumours. Curr Opin Immunol. 27:8–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Akiyoshi T, Gotoh O, Tanaka N, Kiyotani K,
Yamamoto N, Ueno M, Fukunaga Y and Mori S: T-cell complexity and
density are associated with sensitivity to neoadjuvant
chemoradiotherapy in patients with rectal cancer. Cancer Immunol
Immunother. 70:509–518. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ge H, Ferris RL and Wang JH: Cetuximab
responses in patients with HNSCC correlate to clonal expansion
feature of peripheral and tumor-infiltrating T cells with top
T-cell receptor clonotypes. Clin Cancer Res. 29:647–658. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu XS and Mardis ER: Applications of
immunogenomics to cancer. Cell. 168:600–612. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hopkins AC, Yarchoan M, Durham JN, Yusko
EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER and Jaffee
EM: T cell receptor repertoire features associated with survival in
immunotherapy-treated pancreatic ductal adenocarcinoma. JCI
Insight. 3:e1220922018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Postow MA, Manuel M, Wong P, Yuan J, Dong
Z, Liu C, Perez S, Tanneau I, Noel M, Courtier A, et al: Peripheral
T cell receptor diversity is associated with clinical outcomes
following ipilimumab treatment in metastatic melanoma. J Immunother
Cancer. 3:232015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Arakawa A, Vollmer S, Tietze J, Galinski
A, Heppt MV, Bürdek M, Berking C and Prinz JC: Clonality of
CD4+ blood T cells predicts longer survival with CTLA4
or PD-1 checkpoint inhibition in advanced melanoma. Front Immunol.
10:13362019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Han J, Duan J, Bai H, Wang Y, Wan R, Wang
X, Chen S, Tian Y, Wang D, Fei K, et al: TCR repertoire diversity
of peripheral PD-1+CD8+ T cells predicts
clinical outcomes after immunotherapy in patients with non-small
cell lung cancer. Cancer Immunol Res. 8:146–154. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dong N, Moreno-Manuel A, Calabuig-Fariñas
S, Gallach S, Zhang F, Blasco A, Aparisi F, Meri-Abad M, Guijarro
R, Sirera R, et al: Characterization of circulating T cell receptor
repertoire provides information about clinical outcome after PD-1
blockade in advanced non-small cell lung cancer patients. Cancers
(Basel). 13:29502021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Joshi K, Milighetti M and Chain BM:
Application of T cell receptor (TCR) repertoire analysis for the
advancement of cancer immunotherapy. Curr Opin Immunol. 74:1–8.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
McGranahan N and Swanton C: Clonal
heterogeneity and tumor evolution: Past, present, and the future.
Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bendle GM, Linnemann C, Hooijkaas AI, Bies
L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback
E, et al: Lethal graft-versus-host disease in mouse models of T
cell receptor gene therapy. Nat Med. 16:565–570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cercek A, Lumish M, Sinopoli J, Weiss J,
Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M,
Sugarman R, et al: PD-1 blockade in mismatch repair-deficient,
locally advanced rectal cancer. N Engl J Med. 386:2363–2376. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
O'Malley DM, Neffa M, Monk BJ, Melkadze T,
Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW,
et al: Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab
and zalifrelimab combination as second-line treatment for advanced
cervical cancer: An open-label phase II study. J Clin Oncol.
40:762–771. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou
L, Hong R, Tan Su Yin E, Zhang M, Lu P and Huang H: CAR T-cell
therapies in China: Rapid evolution and a bright future. Lancet
Haematol. 9:e930–e941. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Grosser R, Cherkassky L, Chintala N and
Adusumilli PS: Combination immunotherapy with CAR T cells and
checkpoint blockade for the treatment of solid tumors. Cancer Cell.
36:471–482. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pothuri VS, Hogg GD, Conant L, Borcherding
N, James CA, Mudd J, Williams G, Seo YD, Hawkins WG, Pillarisetty
VG, et al: Intratumoral T-cell receptor repertoire composition
predicts overall survival in patients with pancreatic ductal
adenocarcinoma. Oncoimmunology. 13:23204112024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Choudhury NJ, Kiyotani K, Yap KL,
Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y and
O'Donnell PH: Low T-cell receptor diversity, high somatic mutation
burden, and high neoantigen load as predictors of clinical outcome
in muscle-invasive bladder cancer. Eur Urol Focus. 2:445–452. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Jin YB, Luo W, Zhang GY, Lin KR, Cui JH,
Chen XP, Pan YM, Mao XF, Tang J and Wang YJ: TCR repertoire
profiling of tumors, adjacent normal tissues, and peripheral blood
predicts survival in nasopharyngeal carcinoma. Cancer Immunol
Immunother. 67:1719–1730. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Valpione S, Mundra PA, Galvani E, Campana
LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N
and Marais R: The T cell receptor repertoire of tumor infiltrating
T cells is predictive and prognostic for cancer survival. Nat
Commun. 12:40982021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Reuben A, Zhang J, Chiou SH, Gittelman RM,
Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, et al:
Comprehensive T cell repertoire characterization of non-small cell
lung cancer. Nat Commun. 11:6032020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chen C, Liu SYM, Chen Y, Ou Q, Bao H, Xu
L, Zhang Y, Zhong W, Zhou Q, Yang XN, et al: Predictive value of
TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from
ADJUVANT-CTONG 1104 trial. JCI Insight. 7:e1526312022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang J, Bie Z, Zhang Y, Li L, Zhu Y, Zhang
Y, Nie X, Zhang P, Cheng G, Di X, et al: Prognostic value of the
baseline circulating T cell receptor β chain diversity in advanced
lung cancer. Oncoimmunology. 10:18996092021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Abed A, Beasley AB, Reid AL, Law N,
Calapre L, Millward M, Lo J and Gray ES: Circulating pre-treatment
T-cell receptor repertoire as a predictive biomarker in advanced or
metastatic non-small-cell lung cancer patients treated with
pembrolizumab alone or in combination with chemotherapy. ESMO Open.
8:1020662023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Manuel M, Tredan O, Bachelot T, Clapisson
G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret
JF, et al: Lymphopenia combined with low TCR diversity (divpenia)
predicts poor overall survival in metastatic breast cancer
patients. OncoImmunology. 1:432–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yan C, Ma X, Guo Z, Wei X, Han D, Zhang T,
Chen X, Cao F, Dong J, Zhao G, et al: Time-spatial analysis of T
cell receptor repertoire in esophageal squamous cell carcinoma
patients treated with combined radiotherapy and PD-1 blockade.
Oncoimmunology. 11:20256682022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kim JW, Kim S, Yang SY, Joung JG and Hwang
S: T-cell receptor repertoire characteristics associated with
prognostic significance in high-grade serous ovarian carcinoma.
Genes (Basel). 14:7852023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Benítez R, Yu K, Sirota M, Malats N and
Pineda S: Characterization of the tumor-infiltrating immune
repertoire in muscle invasive bladder cancer. Front Immunol.
14:9865982023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lecuelle J, Boidot R, Mananet H, Derangère
V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I,
Ghiringhelli F, et al: TCR clonality and genomic instability
signatures as prognostic biomarkers in high grade serous ovarian
cancer. Cancers (Basel). 13:43942021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Pan M and Li B: T cell receptor
convergence is an indicator of antigen-specific T cell response in
cancer immunotherapies. Elife. 11:e819522022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Aran A, Garrigós L, Curigliano G, Cortés J
and Martí M: Evaluation of the TCR repertoire as a predictive and
prognostic biomarker in cancer: Diversity or clonality? Cancers
(Basel). 14:17712022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Attaf M, Huseby E and Sewell AK: αβ T cell
receptors as predictors of health and disease. Cell Mol Immunol.
12:391–399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Nishida J, Cristea S, Bodapati S, Puleo J,
Bai G, Patel A, Hughes M, Snow C, Borges V, Ruddy KJ, et al:
Peripheral blood TCR clonotype diversity as an age-associated
marker of breast cancer progression. Proc Natl Acad Sci USA.
120:e23167631202023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hiam-Galvez KJ, Allen BM and Spitzer MH:
Systemic immunity in cancer. Nat Rev Cancer. 21:345–359. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Flumens D, Gielis S, Bartholomeus E,
Campillo-Davo D, van der Heijden S, Versteven M, De Reu H, Smits E,
Ogunjimi B, Laukens K, et al: Training of epitope-TCR prediction
models with healthy donor-derived cancer-specific T cells. Methods
Cell Biol. 183:143–160. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chen SY, Liu CJ, Zhang Q and Guo AY: An
ultra-sensitive T-cell receptor detection method for TCR-Seq and
RNA-Seq data. Bioinformatics. 36:4255–4262. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Benotmane JK, Kueckelhaus J, Will P, Zhang
J, Ravi VM, Joseph K, Sankowski R, Beck J, Lee-Chang C, Schnell O
and Heiland DH: High-sensitive spatially resolved T cell receptor
sequencing with SPTCR-seq. Nat Commun. 14:74322023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Baker AM, Nageswaran G, Nenclares P, Ronel
T, Smith K, Kimberley C, Laclé MM, Bhide S, Harrington KJ, Melcher
A, et al: FUME-TCRseq enables sensitive and accurate sequencing of
the T-cell receptor from limited input of degraded RNA. Cancer Res.
84:1560–1569. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Park JH and Lee HK: Function of γδ T cells
in tumor immunology and their application to cancer therapy. Exp
Mol Med. 53:318–327. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Liu Z, Eltoum IEA, Guo B, Beck BH, Cloud
GA and Lopez RD: Protective immunosurveillance and therapeutic
antitumor activity of gammadelta T cells demonstrated in a mouse
model of prostate cancer. J Immunol. 180:6044–6053. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
He W, Hao J, Dong S, Gao Y, Tao J, Chi H,
Flavell R, O'Brien RL, Born WK, Craft J, et al: Naturally activated
V gamma 4 gamma delta T cells play a protective role in tumor
immunity through expression of eomesodermin. J Immunol.
185:126–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chauvin C, Joalland N, Perroteau J, Jarry
U, Lafrance L, Willem C, Retière C, Oliver L, Gratas C,
Gautreau-Rolland L, et al: NKG2D controls natural reactivity of
Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells. Clin
Cancer Res. 25:7218–7228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hao Q, Li R, Li H, Rui S, You L, Zhang L,
Zhao Y, Li P, Li Y, Kong X, et al: Dynamics of the Γδtcr
repertoires during the dedifferentiation process and pilot
implications for immunotherapy of thyroid cancer. Adv Sci (Weinh).
11:e23063642024. View Article : Google Scholar : PubMed/NCBI
|
